Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30407683 | 1.00 | ALDH1A1 (0.54) | ALDH1A1HTTRAB9AHIF1AMAPT | |
| Ethylene SCHEMBL27749093 | 0.96 | HTT (0.51) | ALDH1A1HTTRAB9AHIF1AMAPT | |
| SCHEMBL2602388 | 0.83 | ALDH1A1 (0.50) | ALDH1A1HTTRAB9AHIF1AMAPT | |
| SCHEMBL8568179 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL16657375 | 0.78 | ALDH1A1 (0.70) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL27350487 | 0.77 | ALDH1A1 (0.48) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL2645540 | 0.77 | ALDH1A1 (0.47) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| Ethylene SCHEMBL27749127 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL1351778 | 0.76 | MAPT (0.56) | ALDH1A1HTTRAB9AHIF1AMAPT | |
| SCHEMBL319309 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HTTRAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-105968111-A | Pyridino-imidazole derivatives as well as preparation method and application thereof | 华润赛科药业有限责任公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2014199164-A1 | DIARYL SUBSTITUTED HETEROAROMATIC COMPOUNDS | AMPLA PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-8362019-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyrazine compounds | SPELMAN COLLEGE (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362019-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyrazine compounds | SPELMAN COLLEGE (US) | 2013-01-29 | — | — | US | disclosed |
| US-8334302-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyridine compounds | SPELMAN COLLEGE (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334302-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyridine compounds | SPELMAN COLLEGE (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095009-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095009-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
| EP-0257508-B1 | SUBSTITUTED QUINOXALINES | G.D. Searle & Co. (US) | 1992-09-30 | — | — | EP | disclosed |
| US-4761414-A | TREATMENT OF INFECTIOUS DISEASES CAUSED BY ANAEROBIC BACTERIA | G. D. SEARLE & CO. (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0257508-A1 | Substituted quinoxalines | G.D. Searle & Co. (US) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | MKI67, CCNI, TYMP | ALDH1A1 996/4885HTT 4585/4885RAB9A 3604/4885 |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | ALDH1A1 1646/4885HTT 4337/4885RAB9A 4686/4885 |
| US-20120095009-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | MKI67, CCNI, TYMP | ALDH1A1 1026/4885HTT 4534/4885RAB9A 3787/4885 |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | KCNN3, KCNA4, KCNA3 | ALDH1A1 2760/4885HTT 984/4885RAB9A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.